+0.10  (1%)
Previous Close 7.60
Open 7.55
Price To book 2.28
Market Cap 219420717
Shares 28,496,197
Volume 54,912
Short Ratio 0.25
Av. Daily Volume 81,289

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a to commence 4Q 2017, with top line data expected around year end 2018.
Pre-term labor
Phase 2 trial did not meet primary endpoint in 2016. Phase 3 completion of patient recruitment announced September 6, 2017. Data due 1Q 2018.
Phase 3 trial to be initiated 1H 2017 with data due 1H 2020.
Uterine fibroids
Phase 2b data due mid 2018.

Latest News

  1. ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting
  2. ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule
  3. ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC
  4. Featured Company News - IMRALDI(R), Biogen's Version of AbbVie's Humira(R), Approved in the European Union
  5. Edited Transcript of OBSV.O earnings conference call or presentation 15-Aug-17 9:00pm GMT
  6. ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update
  7. ObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017
  8. An 'Unsung Potential Winner,' ObsEva Initiated At Buy
  9. ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting
  10. What Falling Estimates & Price Mean for ObsEva (OBSV)
  11. ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy
  12. ObsEva SA to Attend Jefferies Healthcare Conference in NYC
  13. ObsEva Reports First Quarter 2017 Financial Results and Business Update